NEW YORK, July 11, 2018 /PRNewswire/ --
According to a research provided by New Frontier Data, the legal cannabis market was worth an estimated USD 8.3 Billion in 2017 and is projected to grow at a compound annual growth rate (CAGR) of 14.7%, to reach an
estimated USD 25 Billion by 2025. The medical cannabis market is projected to grow at a CAGR
of 11.8% through 2025, while sales of cannabis products for recreational use are set to grow at a 18.4% CAGR, from USD 3.2 Billion in 2017 to USD 12.5 Billion by the end of the forecast period.
The research indicates that the data provided is based on the number of states that legalized cannabis for medical or
recreational as of January 2018 and does not include assumptions of additional states legalizing
cannabis by 2025. WeedMD Inc. (OTC: WDDMF), Cara Therapeutics Inc. (NASDAQ: CARA), Cronos Group Inc. (NASDAQ: CRON), Emerald
Health Therapeutics Inc. (OTC: EMHTF), CV Sciences Inc. (OTC: CVSI)
On June 19th, Canada has legalized cannabis on a national
level, and is now the first G20 nation to do so. New Frontier Data Founder & CEO, Giadha Aguirre de Carcer, explained,
"New Frontier Data projects the domestic Canadian cannabis market will reach CAD 9.2 Billion by
2025. Combined, the Canadian medical and adult-use markets will rival that of California - which
boasts the 6th largest overall economy internationally. Canadian usage rates in the medical market are higher on average than in
the U.S. When the adult-use Canadian market opens the combined domestic and international opportunities will increase
dramatically and create new momentum around the world."
WeedMD Inc. (OTC: WDDMF) is also listed on the Toronto Stock Exchange Venture under (TSX-V: WMD). Earlier
last week, the Company announced breaking news that, "it has entered into an agreement with the Alberta Gaming, Liquor &
Cannabis Commission ("AGLC") to supply the province with high-quality, branded cannabis products for sale in Alberta's adult-use market.
'We're proud that the AGLC has selected WeedMD as a cannabis supplier to join its network as it looks to establish a cannabis
framework for its adult-use markets,' said Keith Merker, Chief Financial Officer of WeedMD. 'This
represents a strategic partnership as we look to expand our product reach across the country to support Canada's legal adult-use market. Alberta's high standards align with the
highly-regarded quality of our cultivation standards, product portfolio, and commercial practices as we look to meet the expected
demand of this new market.'
WeedMD will supply the Alberta market with cannabis products starting the first day of legal
sales. This agreement represents a key milestone in WeedMD's strategic plan to develop a national distribution platform for the
Company's medical and adult-use products, building upon the recent announcement of WeedMD's supply agreement with Shoppers Drug
Mart. WeedMD is actively working with provincial distributors, regulators, and retailers to expand its adult-use distribution
program, particularly as the Company completes the final stages of its 220,000 sq. ft. greenhouse retrofit within its 610,000 sq.
ft. greenhouse facility in Strathroy, Ontario. For more information, access our investor
presentation here and corporate video here."
Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and
commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid
receptors (KORs). The Company recently announced positive top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in
patients undergoing abdominal surgeries. At the 1.0 mcg/kg dose, I.V. CR845 demonstrated statistically significant reductions in
pain intensity compared to placebo at all pre-specified post-operative periods of 0-6 hours (p=0.001); 0-12 hours (p=0.004); 0-18
hours (p=0.013); and 0-24 hours (p=0.032). Additionally, I.V. CR845 treatment resulted in statistically significant reductions in
the incidence of post-operative nausea and vomiting over the 24-hour period post-surgery for both 0.x5 and 1.0 mcg/kg doses
(p=0.006; p<0.0001, respectively). "We are very pleased that these data demonstrate the overall benefit of I.V. CR845 in both
providing pain relief across surgery types up to 24 hours post-surgery and reducing post-operative nausea and vomiting, a
significant medical need in the post-operative setting," said Derek Chalmers, Ph.D., D.Sc.,
President and Chief Executive Officer of Cara Therapeutics. "As there continues to be a critical need for new post-surgical
analgesics like I.V. CR845 that lack abuse potential and traditional mu opioid side effects, we will be assessing all options,
including discussions with regulators, as to how to best move this program forward."
Cronos Group Inc. (NASDAQ: CRON) is a globally diversified and vertically integrated cannabis company with a presence
across four continents. On June 25, 2018, the Company announced that it has entered into a
strategic distribution partnership with Delfarma Sp. Zo.o. Founded in 2004, Delfarma is a privately owned pharmaceutical
wholesaler and was the first company in Poland to introduce international parallel import of
medicinal products from European Economic Area countries. Delfarma distributes directly to over 5,000 pharmacies and more than
200 hospitals, a distribution network that reaches approximately 40% of the Polish domestic market. Under the initial five-year
exclusive distribution agreement, Cronos Group's global subsidiaries will supply Peace Naturals branded cannabis products to
Delfarma for distribution within Poland.
Emerald Health Therapeutics Inc. (OTCQX: EMHTF) is a Licensed Producer under Canada's
Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes.
Emerald Health Therapeutics Inc. and Village Farms International Inc. announced on June 27th, 2018
that their 50/50 joint venture for large scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health
Canada an amendment to its cultivation license for its Delta 3 greenhouse in Delta, BC. This amendment permits Pure Sunfarms to substantially expand its cannabis production to 225,000
sq. ft. of the 1.1 Million sq. ft. Delta 3 production facility. In mid-May, Pure Sunfarms
initiated commercial-scale production on 130,000 sq. ft. at the Delta 3 greenhouse, which is now
fully utilized, with harvesting expected to begin in August. Planting in the newly-licensed area will commence this week and is
expected to be completed by the end of July. Pure Sunfarms expects to have the full 1.1 Million sq. ft. Delta 3 facility, one of the single largest cannabis growing facilities in the world, converted to cannabis
production by year end. "The Delta 3 production facility is maturing at an outstanding pace
thanks to our senior cultivation, financial, and operational teams. We are making great strides to achieve large-volume,
high-quality, low-cost cannabis production and anticipate receiving our sales license before the onset of recreational sales on
October 17th," said Chris Wagner, Director, Pure Sunfarms, and Chief
Executive Officer of Emerald Health Therapeutics.
CV Sciences Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on
developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on
manufacturing, marketing and selling plant-based CBD products to a range of market sectors. The Company recently announced the
June 7, 2018 publication of the toxicology and safety results of an extract from the base raw
materials used in its market leading PlusCBD Oil™ consumer products. The Company contracted respected scientific and regulatory
consulting firm, AIBMR Life Sciences Inc., to conduct the battery of toxicological studies to investigate the safety of oral
consumption of the Company's hemp cannabidiol (CBD) oil and to support a Generally Recognized as Safe (GRAS) Independent
Conclusion. The Company's Chief Executive Officer, Joseph Dowling, echoed this sentiment, "We are
thrilled to advance phytocannabinoid science and are very pleased with the safety results from this landmark study. This is an
important milestone in our pursuit of GRAS status," he remarked.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For WeedMD Inc. financial news dissemination and PR services, FinancialBuzz.com has
been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or
negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are
commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of
the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR
advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post
information about any companies the information contained herein is not intended to be used as the basis for investment decisions
and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or
solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or
losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or
presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their
investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and
financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by
the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please
visit: http://www.financialbuzz.com .
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com